Spinogenix Announces U.S. FDA Orphan Drug Designation Granted to SPG601 for the Treatment of Fragile X Syndrome

Press Release Spinogenix Announces U.S. FDA Orphan Drug Designation Granted to SPG601 for the Treatment of Fragile X Syndrome Receiving Orphan Drug Designation for SPG601 emphasizes the pressing demand for novel therapies for individuals living with Fragile X Syndrome LOS ANGELES, Calif., May 20, 2024 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics […]

Spinogenix Announces U.S. FDA Approval of its Investigational New DrugApplication for its Phase 2a Clinical Trial of SPG601 for Fragile X Syndrome

Press Release Spinogenix Announces U.S. FDA Approval of its Investigational New Drug Application for its Phase 2a Clinical Trial of SPG601 for Fragile X Syndrome SPG601 is a once-a-day pill that works by restoring synaptic function to address core symptoms of Fragile X Syndrome LOS ANGELES, Calif., April 15, 2024 — Spinogenix, Inc., a clinical-stage […]

Spinogenix Announces Second Grant Award from U.S. Department of Defense to Further Advance SPG302, the First Synaptic Regenerative Drug to Treat Amyotrophic Lateral Sclerosis (ALS)

Press Release Spinogenix Announces Second Grant Award from U.S. Department of Defense to Further Advance SPG302, the First Synaptic Regenerative Drug to Treat Amyotrophic Lateral Sclerosis (ALS) SAN DIEGO, Calif., Sept. 26, 2023 — Spinogenix, Inc., a clinical-stage biopharmaceutical company developing novel small molecule drugs for neurodegenerative conditions, today announced that it has been awarded […]

Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease

Press Release Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease Treatment Could Help Restore Brain Functions Lost in Many Neurodegenerative Disorders San Diego, CA (September 12, 2023) – Spinogenix, Inc., a clinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today […]

Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Press Release Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS) Treatment Could Help Restore Brain Functions Lost in Many Neurodegenerative Disorders SAN DIEGO, July 10, 2023 (GLOBE NEWSWIRE) — Spinogenix, Inc., […]

Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis

Press Release Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis Treatment Could Help Restore Brain Functions Lost in Many Neurodegenerative Disorders SAN DIEGO, June 07, 2021 (GLOBE NEWSWIRE) — Spinogenix, Inc. a pharmaceutical company focused on the development of novel synaptogenic small molecule therapies for central nervous system […]

Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS)

Press Release Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS) Treatment Could Help Restore Brain Functions Lost in Many Neurodegenerative Disorders SAN DIEGO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) — Spinogenix, Inc. a preclinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today […]